Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

F Pannuti

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Drug Administration Schedule

Activities & Behaviors

Drug Evaluation

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
69
Martoni, Andrea
39
Strocchi, Elena
29
Camaggi, Carlo Maurizio
19
Guaraldi, Monica
19
Lelli, Giorgio
19
Piana, Edera
14
Angelelli, B
11
Zamagni, Claudio
7
Cacciari, N
5
Panetta, A
5
Tanneberger, S
4
Preti, P
4
Mariano, P
3
Giordani, S
3
Robustelli Della Cuna, Gioacchino

Sign-in to see all Coauthors

Publications

TOP 3
Tanneberger S; Malavasi I; Mariano P; Pannuti F; Strocchi E
Planning palliative or terminal care: the dilemma of doctors' prognoses in terminally ill cancer patients.
Tanneberger K S; Pannuti F; Malavasi I; Mariano P; Strocchi E
New challenges and old problems: end of life care and the dilemma of prognostic accuracy.
Guaraldi M; Marino A; Pannuti F; Farabegoli G; Martoni A
Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of F Pannuti (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2002: Tanneberger S; Malavasi I; Mariano P; Pannuti F; Strocchi E
Planning palliative or terminal care: the dilemma of doctors' prognoses in terminally ill cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1320-2; author reply 1322-3.
2002: Tanneberger K S; Pannuti F; Malavasi I; Mariano P; Strocchi E
New challenges and old problems: end of life care and the dilemma of prognostic accuracy.
Advances in gerontology = Uspekhi gerontologii / Rossiiskai?a akademii?a nauk, Gerontologicheskoe obshchestvo 2002;10():131-5.
2001: Guaraldi M; Marino A; Pannuti F; Farabegoli G; Martoni A
Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.
Clinical lung cancer 2001;3(1):43-6; discussion 47-8.
2001: Pinto C; Marino A; Guaraldi M; Melotti B; Piana E; Martoni A; Pannuti F
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
American journal of clinical oncology 2001;24(2):143-7.
1999: Pannuti F; Robustelli della Cuna G; Ventaffrida V; Strocchi E; Camaggi C M
A double-blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group.
Tumori 1999;85(2):96-100.
1999: Cacciari N; Zamagni C; Strocchi E; Pannuti F; Martoni A
Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look.
European journal of gynaecological oncology 1999;20(1):56-60.
1998: Martoni A; Guaraldi M; Piana E; Strocchi E; Petralia A; Busutti L; Preti P; Robustelli G; Raimondi M; Ferrara G; Palomba G; Lelli G; Picece V; Recaldin E; Caffo O; Ambrosini G; Sarobba G; Farris A; Pannuti F
Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1998;22(1):31-8.
1998: Zamagni C; Martoni A; Cacciari N; Gentile A; Pannuti F
The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study.
American journal of clinical oncology 1998;21(5):491-7.
1998: Tanneberger S; Pannuti F
The Bologna Hospital-at-Home: a model for cost-effective care of advanced cancer patients in developing countries.
The National medical journal of India 1998;11(5):231-5.
1998: Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi C M; Pannuti F
Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
Anticancer research 1998;18(4B):2799-803.
1998: Tanneberger S; Pannuti F; Mirri R; Panetta A; Mariano P; Romano D; Giordani S; Martoni A; Farabegoli G
Hospital-at-Home for advanced cancer patients within the framework of the Bologna Eubiosia project: an evaluation.
Tumori 1998;84(3):376-82.
1997: Pironi L; Ruggeri E; Tanneberger S; Giordani S; Pannuti F; Miglioli M
Home artificial nutrition in advanced cancer.
Journal of the Royal Society of Medicine 1997;90(11):597-603.
1997: Bruzzone M; Rubagotti A; Gadducci A; Catsafados E; Foglia G; Brunetti I; Giannessi P G; Carnino F; Iskra L; Rosso R; Martoni A; Pannuti F; De Lisi V; Maltoni R; Ridolfi R; Mammoliti S; Gallo L; Boccardo F; Ragni N; Conte P F
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest.
Gynecologic oncology 1997;65(3):499-505.
1997: Tanneberger S; Pannuti F; Mirri R; Panetta A; Mariano P; Giordani S; Strocchni E; Farabegoli G
[Home hospital for advanced stage cancer patients: costs and benefits]
Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 1997;91(2):117-23.
1997: Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
Chemotherapy of advanced ovarian cancer.
Frontiers in bioscience : a journal and virtual library 1997;2():g20-6.
1996: Cacciari N; Martoni A; Rossi A P; Turci P; Lelli G; Martinelli A; Maver P; Corrado F; Mannini D; Reggiani A; Concetti S; Martelli A; Melotti B; Cricca A; Zamagni C; Pannuti F
A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as primary chemotherapy for locally advanced bladder cancer.
Tumori 1996;82(4):364-8.
1996: Martoni A; Angelelli B; Guaraldi M; Strocchi E; Pannuti F
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):82-5.
1995: Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
European journal of cancer (Oxford, England : 1990) 1995;31A(10):1615-21.
1995: Martoni A; Bidin L; Zamagni C; Cricca A; Pannuti F
Failure to increase 5-fluorouracil activity with interferon-alpha 2a in the treatment of advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):127.
1995: Camaggi C M; Strocchi E; Martoni A; Zamagni C; Cacciari N; Robustelli della Cuna G; Pavesi L; Tedeschi M; Silva A; Pannuti F
Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 1995;36(4):356-9.
1994: Panetta A; Martoni A; Guaraldi M; Tamberi S; Casadio M; Lelli G; Pannuti F
Combined chemo-immuno-hormonotherapy of advanced renal cell carcinoma.
Journal of chemotherapy (Florence, Italy) 1994;6(5):349-53.
1994: Tanneberger S; Panetta A; Pannuti F
How does the message of cancer specialists affect routine medical practice? Only sixty percent of surgical adjuvant breast cancer treatment is based on hormone receptor status.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(8):773-4.
1994: Pedrazzoli P; Zamagni C; Martoni A; Capotorto A M; Da Prada G A; Pavesi L; Preti P; Lelli G; Pannuti F; Robustelli della Cuna G
Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study.
Tumori 1994;80(4):273-5.
1993: Robustelli della Cuna G; Pannuti F; Martoni A; Camaggi C M; Strocchi E; Da Prada G A; Tanneberger S
Aminoglutethimide in advanced breast cancer: prospective, randomized comparison of two dose levels. Italian Cooperative Group.
Anticancer research 1993;13(6B):2367-71.
1993: Martoni A; Panetta A; Angelelli B; Melotti B; Pannuti F
A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.
Journal of chemotherapy (Florence, Italy) 1993;5(1):47-51.
1993: Camaggi C M; Strocchi E; Carisi P; Martoni A; Melotti B; Pannuti F
Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.
Cancer chemotherapy and pharmacology 1993;32(4):301-9.
1993: Pannuti F; Guaraldi M; Martoni A; Melotti B; Morritti M G
Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 2():45-8.
1992: Martoni A; Guaraldi M; Casadio M; Busutti L; Pannuti F
A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(10):864-6.
1992: Zamagni C; Martoni A; Cacciari N; Bellanova B; Vecchi F; Pannuti F
CA-549 serum levels in breast cancer monitoring.
The International journal of biological markers 1992;7(4):217-21.
1992: Tanneberger S; Lelli G; Martoni A; Piana E; Pannuti F
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).
Journal of chemotherapy (Florence, Italy) 1992;4(5):326-31.
1992: Lelli G; Melotti B; Pannuti F; Rossi A P; Maver P; Mannini D; Corrado G; Severini G; Bercovich E; Beghelli R
Chemotherapy with cisplatin, epirubicin, methotrexate in the treatment of locally advanced or metastatic transitional cell cancer of the bladder (TCC).
Journal of chemotherapy (Florence, Italy) 1992;4(4):239-43.
1992: Martoni A; Cricca A; Guaraldi M; Covizzi M; Farris A; Pannuti F
Weekly regimen of 5-FU vs 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancer.
Anticancer research 1992;12(3):607-12.
1992: Pannuti F; Tanneberger S; Lelli G; Piana E
Is ondansetron "too expensive"?
Lancet 1992;339(8793):614-5.
1992: Martoni A; Cricca A; Guaraldi M; Covizzi M; Farris A; Pannuti F
Randomized clinical trial with a weekly regimen of 5-FU vs 5-FU + intermediate-dose folinic acid in the treatment of advanced colo-rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(1):87-8.
1992: Camaggi C M; Strocchi E; Carisi P; Martoni A; Tononi A; Guaraldi M; Strolin-Benedetti M; Efthymiopoulos C; Pannuti F
Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.
Cancer chemotherapy and pharmacology 1992;30(4):307-16.
1992: Camaggi C M; Carisi P; Strocchi E; Pannuti F
High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.
Cancer chemotherapy and pharmacology 1992;30(4):303-6.
1991: Guaraldi M; Martoni A; Tononi A; Occhiuzzi L; Caliceti U; Dall'Olio D; Laudadio P; Pannuti F
5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(5):379-81.
1991: Zamagni C; Martoni A; Ercolino L; Baroni M; Tanneberger S; Pannuti F
5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer.
Journal of chemotherapy (Florence, Italy) 1991;3(2):126-9.
1991: Periti P; Pannuti F; Della Cuna G R; Mazzei T; Mini E; Martoni A; Preti P; Ercolino L; Pavesi L; Ribecco A
Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma.
Cancer investigation 1991;9(3):249-55.
1991: Martoni A; Guaraldi M; Camera P; Biagi R; Marri S; Beghé F; Pannuti F
Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton.
Oncology 1991;48(2):97-101.
1991: Martoni A; Longhi A; Canova N; Pannuti F
High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients.
Oncology 1991;48(1):1-6.
1991: Martoni A; Melotti B; Guaraldi M; Pannuti F
Activity of high-dose epirubicin in advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1231-4.
1990: Lelli G; Guaraldi M; Canova N; Casadio M; Pannuti F
A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC).
Journal of chemotherapy (Florence, Italy) 1990;2(6):401-4.
1990: Casadio M; Lelli G; Giordani S; Boltri B; Blotta A; Busutti L; Ramini R; Falcone F; Pannuti F
Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide.
Journal of chemotherapy (Florence, Italy) 1990;2(3):199-202.
1990: Martoni A; Ercolino L; Bellucco A; Canova N; Lelli G; Pannuti F
Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer.
Journal of chemotherapy (Florence, Italy) 1990;2(1):62-6.
1990: Martoni A; Piana E; Guaraldi M; Cilenti G; Farris A; Saccani F; Becchi G; Pannuti F
Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer.
Oncology 1990;47(5):427-32.
1990: Martoni A; Melotti B; Guaraldi M; Pacciarini M A; Riva A; Pannuti F
High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
European journal of cancer (Oxford, England : 1990) 1990;26(11-12):1137-40.
1989: Lelli G; Tononi A; Bacchetti P; Maver P; Corrado G; Garofalo F; De Santis P; Pannuti F
Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.
Journal of chemotherapy (Florence, Italy) 1989;1(4):269-71.
1989: Martoni A; Cricca A; Guaraldi M; Farris A; Pannuti F
A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report.
Journal of chemotherapy (Florence, Italy) 1989;1(3):197-202.
1989: Lelli G; Casadio M; Farris A; Tononi A; Giordani S; Pannuti F
A phase III study on intermittent versus weekly cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
Journal of chemotherapy (Florence, Italy) 1989;1(2):136-9.
1989: Martoni A; Bellucco A; Canova N; Pannuti F
Four-year analysis of platinum and anthracycline combination for ovarian cancer.
Oncology 1989;46(2):109-16.
1988: Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1988;7(5):345-9.
1988: Guaraldi M; Martoni A; Rossi A P; Romagnoli D; Occhiuzzi L; Caliceti U; Pannuti F
Treatment of advanced head and neck tumors with PEV-B regimen: a pilot study.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1988;7(5):341-4.
1988: Martoni A; Ercolino L; Bellanova B; Zanichelli L; Canova N; Pannuti F
CA 15.3 and CEA plasma level monitoring in patients with breast cancer.
The International journal of biological markers 1988;3(3):154-8.
1988: Pannuti F; Coppi G; Borella F; Martoni A; Urbano L; Melotti B
Pharmacokinetics of PTT-119 in man.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1988;7(2):113-6.
1988: Pannuti F; Martoni A; Cilenti G; Camaggi C M; Fruet F
Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
European journal of cancer & clinical oncology 1988;24(3):423-9.
1988: Camaggi C M; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
Cancer chemotherapy and pharmacology 1988;21(3):221-8.
1988: Camaggi C M; Comparsi R; Strocchi E; Testoni F; Pannuti F
HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids.
Cancer chemotherapy and pharmacology 1988;21(3):216-20.
1987: Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(6):396-8.
1987: Lelli G; Casadio M; Giordani S; Giuliotti C; Canova N; Martoni A; Pannuti F
4'-Epidoxorubicin plus cisplatin as first-line therapy in the treatment of small cell bronchogenic carcinoma.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(2):134-6.
1987: Pannuti F; Camaggi C M; Strocchi E; Comparsi R
Medroxyprogesterone acetate plasma pharmacokinetics after intravenous administration in rabbits.
Cancer chemotherapy and pharmacology 1987;19(4):311-4.
1986: Martoni A; Pacciarini M A; Piana E; Pannuti F
A pilot study of oral idarubicin in metastatic melanoma.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1986;5(6):414-5.
1986: Pannuti F; Camaggi C M; Strocchi E; Comparsi R; Rossi A P; Angelelli B; Franchini A
Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic study.
European journal of cancer & clinical oncology 1986;22(11):1309-14.
1986: Martoni A; Bellucco A; Marabini A; Orlandi C; Platé L; Bianchi D; Pannuti F
CA-125 monitoring during chemotherapy for ovarian cancer.
The International journal of biological markers 1986;1(3):121-8.
1986: Lelli G; Casadio M; Giuliotti C; Giordani S; Martoni A; Strocchi E; Pannuti F
Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1986;5(4):228-31.
1986: Pannuti F; Strocchi E; Longhi A; Comparsi R; Camaggi C M
Medroxyprogesterone acetate plasma levels after a single oral administration of two drug formulations.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1986;5(4):237-9.
1986: Pannuti F; Vancini B; Comparsi R; Strocchi E; Camaggi C M
Rectal administration of medroxyprogesterone acetate in cancer patients: a pharmacokinetic study.
Cancer treatment reports 1986;70(7):937-8.
1986: Camaggi C M; Strocchi E; Comparsi R; Testoni F; Angelelli B; Pannuti F
Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients.
Cancer chemotherapy and pharmacology 1986;18(1):47-50.
1986: Pannuti F; Camaggi C M; Strocchi E; Comparsi R; Angelelli B; Pacciarini M A
Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Cancer chemotherapy and pharmacology 1986;16(3):295-9.
1985: Martoni A; Pacciarini M A; Pannuti F
Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
European journal of cancer & clinical oncology 1985;21(7):803-6.
1985: Pannuti F; Ferrari P; Fruet F; Marrano D; Piana E
[New trends in hormone therapy]
Pathologica 1985;77(1049):347-8.
1985: Pannuti F; Martoni A; Farabegoli G; Piana E
Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1985;4(2):127-34.
1985: Pannuti F; Martoni A; Lelli G; Camaggi C M; Strocchi E; Fruet F
[New anthracyclines in the treatment of solid tumors in the advanced stage]
Giornale italiano di chemioterapia 1985;32(1):49-56.
1985: Periti P; della Cuna G R; Pannuti F; Mazzei T; Preti P; Martoni A; Mini E
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
Investigational new drugs 1985;3(2):167-71.
1985: Martoni A; Pacciarini M A; Pannuti F
The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Drugs under experimental and clinical research 1985;11(2):127-31.
1985: Camaggi C M; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
Drugs under experimental and clinical research 1985;11(4):285-94.
1985: Camaggi C M; Strocchi E; Costanti B; Beghelli P; Ferrari P; Pannuti F
Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.
Cancer chemotherapy and pharmacology 1985;14(3):232-4.
1985: Camaggi C M; Strocchi E; Canova N; Costanti B; Pannuti F
Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.
Cancer chemotherapy and pharmacology 1985;14(3):229-31.
1985: Strocchi E; Camaggi C M; Rossi A P; Angelelli B; Comparsi R; Franchini A; Del Prete P; Cola B; Pannuti F
Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration.
Drugs under experimental and clinical research 1985;11(4):295-301.
1985: Pannuti F; Martoni A; Murari G; De Sanctis R; Fruet F; Strocchi E
Analgesic activity of medroxyprogesterone acetate (MAP) in cancer patients: an antiinflammatory mediated activity?
International journal of tissue reactions 1985;7(6):505-8.
1984: Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Cancer treatment reports 1984;68(11):1391-3.
1984: Lelli G; Angelelli B; Zanichelli L; Strocchi E; Mondini F; Monetti N; Piana E; Pannuti F
The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1984;3(5):327-9.
1984: Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1984;3(4):216-9.
1984: Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1984;3(4):211-5.
1984: Pannuti F; Cricca A; Marraro D; Rossi A P; Fruet F; Casadio M
[Medical therapy of pain in oncology]
Minerva medica 1984;75(24):1451-61.
1984: Martoni A; Tomasi L; Farabegoli G; Giovannini M; Monetti N; Ganzina F; Pannuti F
A phase II study of 4'-epi-doxorubicin plus cis-platinum in advanced solid tumors.
European journal of cancer & clinical oncology 1984;20(1):11-7.
1984: Martoni A; Giovannini M; Tomasi L; Camaggi C M; Bellanova B; Monetti N; Rossini G; Tarquinii M; Martini A; Pannuti F
A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
Cancer chemotherapy and pharmacology 1984;12(3):179-82.
1983: Lelli G; Angelelli B; Giambiasi M E; Colalongo F; Camaggi C M; Costanti B; Strocchi E; Pannuti F
The anabolic effect of high dose medroxyprogesterone acetate in oncology.
Pharmacological research communications 1983;15(6):561-8.
1983: Pannuti F; Piana E; Palenzona D; Lenaz G R; Rocchetta G; Nanni P; Rubino I; Murari G; Martoni A; Saccani Joti G
The prevention of the cardiotoxic effects of adriamycin by means of strophanthin. Preclinical study (chick embryo test).
Panminerva medica 1983;25(1):1-6.
1983: Camaggi C M; Strocchi E; Giovannini M; Angelelli B; Costanti B; Zebini E; Ferrari P; Pannuti F
Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
Cancer chemotherapy and pharmacology 1983;11(1):19-22.
1982: Pannuti F; Camaggi C M; Strocchi E; Giovannini M; Di Marco A R; Costanti B
Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients.
Cancer treatment reports 1982;66(12):2043-9.
1982: Pannuti F; Di Marco A R; Martoni A; Fruet F; Strocchi E; Burroni P; Marraro D
[Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages]
Minerva ginecologica 1982;34(11):977-9.
1982: Camaggi C M; Strocchi E; Tamassia V; Martoni A; Giovannini M; Lafelice G; Canova N; Marraro D; Martini A; Pannuti F
Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.
Cancer treatment reports 1982;66(10):1819-24.
1982: Martoni A; Giovannini M; Pollutri E; Burroni P; Saccani-Jotti G; Pannuti F
[Effect of medroxyprogesterone acetate (MAP) in high doses on chlorambucil-induced bone marrow depression. Preliminary results]
Archivio per le scienze mediche 1982;139(4):449-53.
1982: Pannuti F; Martoni A; Busutti L; Gramellini M; Piana E
High-dose medroxyprogesterone acetate in advanced male breast cancer.
Cancer treatment reports 1982;66(9):1763-5.
1982: Pannuti F; Martoni A; Fruet F; Di Marco A R; Piana E; Saccani-Jotti G; Manfredi D; Mattioli G; Barbanti F; Battelli T; Franchini A; Marrano D; Lungarotti F; Bergnach A
Surgical adjuvant hormonal therapy with high dose medroxyprogesterone acetate (MAP) in breast cancer. Results 36 months after mastectomy.
Panminerva medica 1982;24(3):187-94.
1982: Pannuti F; Rossi A P; Iafelice G; Marraro D; Camera P; Cricca A; Strocchi E; Burroni P; Lapucci L; Fruet F
Control of chronic pain in very advanced cancer patients with morphine hydrochloride administered by oral, rectal and sublingual route. Clinical report and preliminary results on morphine pharmacokinetics.
Pharmacological research communications 1982;14(4):369-80.
1982: Pannuti F; Camaggi C M; Strocchi E; Giovannini M; Canova N; Murari G
Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients.
Cancer chemotherapy and pharmacology 1982;9(2):122-3.
1981: Pannuti F; Martoni A; Fruet; Marraro D; Strocchi E
New regimen of combination hormone therapy (ME-TA-MAP) in the treatment of advanced breast cancer. A pilot study.
Panminerva medica 1981;23(3):157-60.
1981: Pannuti F; Di Marco A R; Rossi A P; Rocchetta G; Rubino I; Giovannini M; Fruet F
Sequential hormone-chemotherapy (MAP at high doses and CMF) in metastatic breast cancer. Preliminary results.
Panminerva medica 1981;23(2):93-6.
1981: Pannuti F; Rossi A P; Di Marco A R; Fruet F; Lelli G; Strocchi E; Rocchetta G; Piana E; Martoni A
Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot study.
Panminerva medica 1981;23(1):25-8.
1981: Pannuti F; Gaggi R; Murari-Colalongo G; Burroni P; Fruet F; Cricca A; Camaggi C M
Experimental study on the anabolic and androgenic/antiandrogenic activity of different dose levels of medroxyprogesterone acetate (MAP) in rats.
Oncology 1981;38(5):307-10.
1980: Pannuti F; Lelli G; Casadio M; Piana E; Di Marco A R
High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial.
Cancer treatment reports 1980;64(10-11):1131-4.
1980: Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses]
Minerva medica 1980;71(31):2215-9.
1980: Pannuti F; Burroni P; Fruet F; Piana E; Strocchi E; Di Marco A R; Cricca A; Camaggi C M
Anabolizing and anti-pain effect of the short-term treatment with medroxyprogesterone acetate (MAP) at high oral doses in oncology.
Panminerva medica 1980;22(3):149-56.
1980: Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco A R
Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
European journal of cancer 1980;Suppl 1():93-8.

Sign-in to see more